Heartflow CFO Vikram Verghese sells $1.75M in stock
HeartFlow CFO Vikram Verghese sold $1.75M in shares from September 11-15, 2026, under a 10b5-1 plan. Shares sold at $50.012-$50.2381 each. HeartFlow's stock is near its 52-week high, up 130% in six months. The company reported 43% revenue growth but remains unprofitable. Q2 2026 revenue was $64.1M, beating estimates. Stifel raised its price target to $45 with a Buy rating.
How this was made
The 30-second read
Why it matters
The insider sale adds a short‑term bearish nuance to an otherwise positive earnings narrative.
Market read
Insider sale introduces modest downside risk amid broader positive earnings momentum.
What to watch
Strong Q2 earnings and analyst target raise may offset sell pressure.
Background
HTFL reported strong Q2 results and raised price target, while CFO executed a pre‑arranged stock sale.
Ticker impact
CFO Vikram Verghese sold $1.75M of HTFL stock under a Rule 10b5‑1 plan, disclosed for the first time.
Modest downside pressure over the next few days.
Insider sale by CFO suggests reduced confidence; size is modest but may trigger short‑term sell‑off.
Market effects
Limited impact on medical‑technology sector; similar insider sales may be watched.
Minimal, primarily US market focus.
Low
Counterpoint
Sale could be routine under a pre‑arranged plan, not indicative of fundamentals.
Key entities
- companyHeartFlow, Inc.
Medical‑technology firm (NASDAQ:HTFL).
- personVikram Verghese
Chief Financial Officer of HeartFlow.
